{"name":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","slug":"jiangxi-qingfeng-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Aolanti Weipang Tablets","genericName":"Aolanti Weipang Tablets","slug":"aolanti-weipang-tablets","indication":"Phase 2 clinical trials for Aolanti Weipang Tablets are ongoing, but specific indications are not publicly disclosed.","status":"phase_2"},{"name":"Aolanti Weikang tablets","genericName":"Aolanti Weikang tablets","slug":"aolanti-weikang-tablets","indication":"Other","status":"phase_1"},{"name":"Azithromycin plus Xiyanping injection","genericName":"Azithromycin plus Xiyanping injection","slug":"azithromycin-plus-xiyanping-injection","indication":"Other","status":"phase_1"},{"name":"andrographolide sulfonate","genericName":"andrographolide sulfonate","slug":"andrographolide-sulfonate","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Standard treatment+Xiyanping injection","genericName":"Standard treatment+Xiyanping injection","slug":"standard-treatment-xiyanping-injection","indication":"Viral infections (adjunctive therapy)","status":"marketed"},{"name":"andrographolide sulfonate simulation","genericName":"andrographolide sulfonate simulation","slug":"andrographolide-sulfonate-simulation","indication":"Upper respiratory tract infection","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"GP681","genericName":"GP681","slug":"gp681","indication":"Type 2 diabetes","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"GP681 Simulant","genericName":"GP681 Simulant","slug":"gp681-simulant","indication":"Attention Deficit Hyperactivity Disorder (ADHD)","status":"phase_3"}]}],"pipeline":[{"name":"Standard treatment+Xiyanping injection","genericName":"Standard treatment+Xiyanping injection","slug":"standard-treatment-xiyanping-injection","phase":"marketed","mechanism":"Xiyanping injection is a traditional Chinese medicine extract that exerts anti-inflammatory, antiviral, and immunomodulatory effects through multiple pathways.","indications":["Viral infections (adjunctive therapy)","Inflammatory conditions (adjunctive therapy)","Hand, foot and mouth disease","Respiratory tract infections"],"catalyst":""},{"name":"Aolanti Weipang Tablets","genericName":"Aolanti Weipang Tablets","slug":"aolanti-weipang-tablets","phase":"phase_2","mechanism":"Aolanti Weipang Tablets' mechanism of action is not publicly available.","indications":["Phase 2 clinical trials for Aolanti Weipang Tablets are ongoing, but specific indications are not publicly disclosed."],"catalyst":""},{"name":"GP681","genericName":"GP681","slug":"gp681","phase":"phase_2","mechanism":"GP681 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Aolanti Weikang tablets","genericName":"Aolanti Weikang tablets","slug":"aolanti-weikang-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Azithromycin plus Xiyanping injection","genericName":"Azithromycin plus Xiyanping injection","slug":"azithromycin-plus-xiyanping-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GP681 Simulant","genericName":"GP681 Simulant","slug":"gp681-simulant","phase":"phase_3","mechanism":"GP681 Simulant is a stimulant medication that works by increasing the levels of certain neurotransmitters in the brain.","indications":["Attention Deficit Hyperactivity Disorder (ADHD)"],"catalyst":""},{"name":"andrographolide sulfonate","genericName":"andrographolide sulfonate","slug":"andrographolide-sulfonate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"andrographolide sulfonate simulation","genericName":"andrographolide sulfonate simulation","slug":"andrographolide-sulfonate-simulation","phase":"marketed","mechanism":"Andrographolide sulfonate is a water-soluble derivative of andrographolide that exerts anti-inflammatory and immunomodulatory effects through multiple cellular pathways.","indications":["Upper respiratory tract infection","Acute bronchitis","Inflammation-related conditions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNVXpCV25oMmg5aTBBVVZ2cGd1OG9aLUR0aTJJQ2ZHeXQ2TWdHU0gweVlLZ2dXbmVhLXlCaG55X1d2M18yT1J2bk5QbEtXY0JoYWZtbmVrWV96MHVBcW4yOWNaMDhVbWtDTGh1Vkc1UG05em1PaGhVYVRpcFZmbUhCaXBYVU5NcGNXbGljY29fSVUwTzhabmUzSDg3OXk1RS1zc0drUFBPSXJ5WFVyVmZ4RXRVSG92Tk11cFJoVG5sdmFxZTNJdk4wNmQ1VTBGSnNUZ09fbXN4NGpRZEgxYUJzZURPclZ3WnFjNlhaclEwWXBCSGZqdC1QMzNaMXU?oc=5","date":"2026-04-07","type":"trial","source":"Barchart.com","summary":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com","headline":"Influenza Clinical Trial Pipeline Accelerates as 120+ Pharma Companies Rigorously Develop Drugs for Market Entry | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNdEhBRDBMUENUUHhEM1Q1TDdXb0l2ZU1mNkc3bDUtdjNPU1FVMnpoM1VId3o0czljM0RqUmJ2cEUxekxha2ZjQkZ6b0Z4bEhxSmNvai04X2MwWlFrTW1pTjE5elduTnJvWWJlY05LbHJZQVVVRTM2OVFTSFJScWliM212bXJWWWozQ2tHeDBuUnExS2V0cUlJSFFPdmRaTHFPMTNWVUhnMXU1eEItZllhaEs1TjVsZmlfYU9WaVVqa3FoWjg5UzlMdThBODdmZFdrUVNsXzFLYUw1MVdRV1c3QzAtS2pVVFJ2aHZGTjJuSU00SHhuVUlUb0drUm1oWGJpZUVrYndB?oc=5","date":"2025-10-09","type":"pipeline","source":"PR Newswire","summary":"Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight - PR Newswire","headline":"Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxOVE85QlhZaUcxdWVBeHZGaHZxcWJ6N21naFV1cTFROExZRS1nRjRadnQwZWpfMlVJLTl0aW94VExXUkxDSDFfZEY5V01WLVVDSjJTS1lvbUJaWnBtQ2FDQXphODFXeEtUdjJRVHllUEp3WlpYQlluQWpuWlE3TWZmYnNJT0tSazY2OVprRS1BTV9VQzdQQnQ5d1RRVXpaSnJ4RjJRaXhoNkYzbURUMEFWeHZJZmhsRGdRUng4djFZUTNXVWd4b19fUDJxNnhkeTNWQ09kaVZIVk1zUTNNQm5DYTV6YzFnNFFhTnVrTEhjMmFwQzZXdjNTMHhSRTdsRkxhaVZhcXlZbm5YRU9uSHljc2VIQmNBWGpMSjlnb09WcTgtU0x2c0FUV0Y3aUc?oc=5","date":"2025-05-08","type":"pipeline","source":"GlobeNewswire","summary":"High- and Low-Grade Serous Ovarian Cancer Market is - GlobeNewswire","headline":"High- and Low-Grade Serous Ovarian Cancer Market is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxOT3V0UTc3SUE5NDZKYmcxR292V2pYcVhMWjlfaGRfZlpqYTlQYzhRd3RoNXI3N3doZU5ReEVoZmI4RUlBYkM2VWJwNnFWc2xwajk0eWp4RWJvWnZVS1NrRlJuOHlVX1BxQmZPWXMwWFRKWjBpU240ajlrUzNpcWpwR05RMUtycGNUMHZmOHRMWEtNS1NxLUxmNXJxWnlPREhkbThuS0RSSU15cWM5ZUJUam0zd3ZhOGJVaTB3TDl2WTlBMHFKNzZ1NDFpaXNUYzM2LWgtcUl4VHNNbm8yWVc1SVZTT1ota2ZJb3RZVGphY0hOR2FsZ1R5MWs4NVk3MEVYd1dWMk8xSEIwRUZJ?oc=5","date":"2025-04-24","type":"pipeline","source":"PR Newswire","summary":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | DelveInsight - PR Newswire","headline":"IBRANCE's Market Growth Marks a Significant Step Forward in Metastatic HR+/HER2− Breast Cancer Treatment Landscape | Del","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-10-02","type":"regulatory","source":"GlobeNewswire","summary":"SERD Market is Predicted to Exhibit Remarkable Growth Owing - GlobeNewswire","headline":"SERD Market is Predicted to Exhibit Remarkable Growth Owing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxNbDVNY2Vtekhac0k0RU5Rc0hGN3FTVFA2UTRaMlRvbnduYW54TEtEUFpmdjIzYWUxQ1k1Rmt4R3JtVEtPTkFQMWRhTmxtOEctdGJMN0RCSlJ2dWxsWWRkN0xucC1ETkxZSnhEX0JEeGZVTXpTMjZSeDJwbWphbGRQa3lNTEFkTG5XOUZDZ1ZSa0JXWFlUbGFhRDZ0M29QSlIxQUg1Rk8wMXlUUEFEWG5CQndyS0tDQVp2T2tmM0lzeTZRSEtIbk1DVzY3ZWVpX0RZcWJ6MWtSS0FJd21JTTNwVXcxeHpBSXJlVHl3MmIxMUtlQWVLaVlfTVhvWUdobkRiVDFTM0pkWTFYSHo4RjN3TU1VYUV5dk1XZjRya3ptcUwwREpUamVveE9QYU4zSUxSU3djOWZNTQ?oc=5","date":"2024-10-01","type":"trial","source":"GlobeNewswire","summary":"Breast Cancer Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"Breast Cancer Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZ1R2OG0yX293dnl5YVhwS3UtcmtBQ0wzaFFFMVZBcVA0TmFZQnFJUXNKYjBNVEJoMkE1dlFjcXRVRTNhSk8tLUgzZjl3MkJMZFJIOTV4QzdhVWJMUmtqZXQwai1QLXVqNk50cUF4TkJtaDlUOHdkaUFtM3Ixak4tYm5JRjl5VHVJaHloSFFYN25RTkM5S2NvOWlIT250bDA5MEloU2phQm5TZklCdEFzQ2c3ZGdfWHF0eThURTMyOW1LSXRzVGpOaENhWFBzVHNyRzlEamp1RU96bW5vZWc0?oc=5","date":"2024-09-25","type":"pipeline","source":"PR Newswire","summary":"CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight - PR Newswire","headline":"CDK 7 Inhibitors Market is Expected to Showcase a Significant Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQbnFfbDU2Vlc0ZW9BcnItOVEta2p2eVBmM3FaaFFERG5CS0tRd2JBd2ZtWXNOd0lXMEZYNG55LS1SaF82T3ltWDFnV2JVQmQzODJjT0RHSGdDOS1LcGJzemZzV2I2cjI1NnVEV0FFSFBKQXhVT05xZlhQQmxWMGNzTjYyOUtnUHczRGdCaTlCQjdjZ3FpbTZyaXZDdktWeWVKc09feVNtbVc5bEVGS09PR29ZSk52Z0t3UkhvbHFDZ2UtWHh3YklxYk45RUo3c1UtOUVZX0FILVozU1MzZTFfREZaYmo1dw?oc=5","date":"2022-08-31","type":"pipeline","source":"PR Newswire","summary":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight - PR Newswire","headline":"Influenza Pipeline Looks Promising as 100+ Companies Working in the Domain, Assesses DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"marketed":3,"phase_2":2,"phase_1":2,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}